Guy Sauvageau

The paper investigates structural variant induction in human hematopoietic stem and progenitor cells during HDR-enhanced CRISPR editing, finding that SVs occur even without DNA-PK inhibitors and increase with multiple edits.

The paper presents a chemical-genetic interaction matrix derived from CRISPR/Cas9 screens, revealing drug mechanisms and genetic architecture in human cells.

This study edits the CD33 epitope in cord blood HSPCs to reduce toxicity from CD33-targeted therapies while maintaining anti-leukemic efficacy.

EPCY ranks genes by predictive power using cross-validated classifiers and density estimation, outperforming DEG-based methods in selecting robust candidate genes.

This study identifies DEK::NUP214 as an XPO1-dependent transcriptional activator of leukemia genes, showing selective response to XPO1 inhibitors in t(6;9) AML cases.

The paper replicates a GWAS signal near HLA-DQA2 associated with AML risk using a disease-only cohort and external population-based controls, finding a stronger effect in patients with NPM1 mutations.

SPAT annotates proteins based on their likelihood to be at the cell surface using existing annotations, showing good performance on leukemia and public datasets.

This paper evaluates how dimensionality reduction techniques and gene signatures affect Cox-Proportional-Hazard models for AML prognosis using the Leucegene dataset.

This study identifies HLF as a specific marker for human hematopoietic stem cells and develops a genomic reporter system to track its expression.

The paper identifies Mubritinib as an ETC1 inhibitor effective against chemotherapy-resistant AML subtypes with OXPHOS hyperactivity and specific mutations.

This paper introduces km, a method for detecting targeted mutations in AML using unaligned RNA-Seq reads, showing it is fast, accurate, and limited by sequencing depth.